Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...
Roche's experimental drug fenebrutinib achieved significant results in a Phase III trial for primary progressive multiple sclerosis (PPMS), reducing the risk of disability progression by 12%. This ...
Cerebral palsy represents one of the clearest opportunities in modern medicine to reduce lifelong disability, control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results